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aeruginosa has been the sole species prone to develop imipenem resis- 
tance, acheved by loss of a speclhc porin, OprD. Loss of OprD 
also raises the MIC of meropenem, though rarely above break- 
point, but does not affect MICs of penicilLns or cephalosporins. 
By contrast, MICs of meropenem, p e n i c h  and cephalosporins - 
not those of imipenem - are raised for I! amginosa strains with in- 
creased function of the MexA-Me&-OprM multi-drug efflux sys- 
tem. New modes of carbapenem resistance are emerging and may 
present future problems: IMP-1, a plasmidic zinc b-lactamase, is 
spreading in gram-negative rods in Japan, and various modes of re- 
sistance occur in Acinetobacter spp. New carbapenems-sanfetrinem 
and L-749,345- are in advanced development. Sanfetrinem, an 
oral agent, has anti-gram positive activity resembling inupenem 
but is slightly less active vs. gram-negative pathogens; L-749,345 
has s d a r  activity to meropenem, except us. Z? aeruginosa, but has 
pharmacokinetics resembling cefuiaxone. Experimental carbapen- 
ems bind PBP-2‘ of MRSA, and have MICs 50.03 mg/L for 
highly penicillin-resistant pneumococci. No described carbapenem 
escapes IMP-1 p-lactamase, but it may be overcome with new in- 
hibitors. 
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1 S116 I Current needs in mycobacteriology 
M. Saltinger. Wadsworth Center, New York State Dept. $Health and 
Albany Medical college, Albany, NE: U S A  
During the last decade, the industrialized nations have experienced a 
well-publicized tuberculosis (TB) epidemic. By the same token, the 
occurrence of new species of nontuberculous mycobacteria (NTM) 
have challenged the microbiology laboratories’ capability to provide 
accurate results in a timely fashion. Furthermore, the economic cli- 
mate pun an additional spin on the charge placed on laboratories 
providing clinical services. Once a diagnosis of mycobacterial &ease 
in a patient is suspected, a series of interactions between the clinician 
and the laboratory are set into motion. The following three topics 
require attention: 1) In patients with acid-fast bacilli smear-positive 
sputum specimens diagnosed for the first time, the Meentiation 
between TB and NTM is imperative (respiratory isolation, adequate 
drug regimen, and contact investigation); 2) in areas with increased 
drug resistant TB susceptibility testing results, especdy for rifampin, 
are paramount; and 3) the emergence of chcaIly sigruficant NTM, 
especially in immuno-comprised hosts, poses an additional challenge 
for patient care. The foundations of the clinical mycobacteriology 
laboratory of the next millennium are: a) testing and prioritizing 
hgh-quality specimens, b) joining the acid-fast network to provide 
accurate results in a timely fasluon, and c) bridgmg the gap between 
physicians, laboratorians, and public health officds in order to im- 
prove the service rendered for our patients. As the adage goes “That 
which is worth doing is worth doing right”. 
LS117 I Mycobacterial Screening of Non-Blood and 
Blood Specimens Using (Semi) Automated 
Mycobacteria Detection Systems 
R. Freeman. Newciz.de Public Health Luboratoy, Newca.de upon Tyne, 
UK 
The use of liquid media for primary isolation has always had a place 
in mycobacteriology. However, the lnherent dangers ofliquid culture 
(compared with solid cultures), the increased difficulties with con- 
tamination and the laboriousness of observation for signs of p w t h  
have all dictated that liquid culture be reserved for a small minority 
of specimens and particularly those fiom ordmarily sterile sites such 
as the spinal fluid. 
Modern approaches to liquid cultures, partly driven by earlier 
work on non-mycobacterial organisms, have resulted in the develop- 
ment of automated or semi-automated liquid culture systems which 
are securely contained and highly selective. The addition of highly 
sensitive growth monitoring technology has ensured that the pres- 
ence of mycobacteria in these systems can be detected at far shorter 
intervals than hitherto. In many instances it is now possible to grow 
mycobacteria, including Mycobaderium tuberculosis, within 2 weeks of 
specimen receipt. 
Several Merent approaches have been developed. T h  presen- 
tation will contrast and compare these, looking particularly at the 
speed and accuracy of detection, the incidence of contamination, 
the ease of usage and the immediate usefulness of the detected liquid 
culture biomass for further investigations (genetic probe identifica- 
tions, antibiotic susceptibihties, and so on). The presentation will 
also consider the optunal use for these novel but expensive methods, 
using data generated by a large ongoing study, and balancing issues 
of cost and safety against the undoubted advantages of this important 
advance in mycobacteriology. 
I S118 I Drug Susceptibility Testsfor M. tuberculosis 
L. Heifets, F! Lindhoh-Levy, T. Sanchez, J. Brennan, L. Gomelsky. 
NationalJetuiih Med. Res. Cfr, Denver, CO, U S A  
Objectives: To evaluate the liquid media-based systems for rapid 
indirect drug susceptibihty tests with M .  tuberculosis. 
Methods: New systems for mycobacterial cultivation, h4B/BacT 
fiom Organon T e e ,  ESP fiom Difco and MGIT &om Bec- 
ton-Dickinson, were evaluated in comparison with 7 H l l  agar and 
Results: All methods tested are suitable for isolation of mycobac- 
teria and for indirect susceptibility testing with M .  tuberculosis, but 
the critical concentrations ofsome drugs require further adjustments. 
Timing for isolation and the indirect susceptibility test in new sys- 
tems upds sigdicantly shorter than on agar plates, but it was 2 to 5 
days longer than in the BACTEC-460 system. 
Conclusions: Liquid media systems have the potential to expe- 
dite the diagnosis of tuberculosis and detection of drug resistance. 
The added cost can be justhed only for initial specimens fiom new 
patients if tested in large laboratories. Indmect testing in any liquid 
media should not replace the direct test on 7Hl l  agar plates for 
AFB-positive specimens. 
BACTEC-460. 
Molecular technologies in diagnostic 
mycobacteriology 
A. Telenti. Institutefor Medial Microbiolon, University $ Bern, 
Switzerland 
A number of molecular techniques have recently been made avail- 
able in mycobacteriology. Various key questions should be answered 
before routine implementation of these tools: 
(a) which techniques are reliable, and for which purpose? 
(b) who should perform them? 
(c) will they influence patient management? 
(d) are they cost-effective for the proposed setting? 
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A conservative position would be the following: 
God Technique Laboratory LNcl Efficiency 
Early detection DNA, RNA Not esubhshed Quertiomble 
amplificaaon 
Sequencing 
Speder idcntification Accuprobe. PCR-RFLF’, RL Yes 
Raiunce tesring Genotype testmg RL in areas YCS 
with MDR-TB 
Epldcmiology a d  
quality control W L P  RL YCS 
RL: Reference Laboratory 
At today‘s costs and lutllted automation, the conditions for an 
effective implementation of these techniques are generally only ful- 
filled by reference laboratories. 
Towards consensus in sensitivity testing 
ESCMID Working Party on Antibiotic 
Breakpoints, Interactive Session 
1 s1201 Problems in susceptibility testing: looking for a 
consensus 
F. Goldstein ’, F. Baquero ’, R. A~ckenthaler~. ’HGpital St.-joseph, 
Paris, France, ‘Hospital Ramon y Cajal, Madrid, Spain, ’HGpital 
Cantonal, Genbe, Switzerland 
Antibiotic susceptibility testmg varies &om country to counby ac- 
cordmg to the recommendations of national antimicrobial suscepti- 
bility testing committees. 
Objectives: To obtain the reactions fium the participating audi- 
ence in order to achieve a consensus for future susceptibility testing. 
Methods: This session will use an interactive audience response 
system to create a dynamic exchange between the audiences and 
the speakers. Following subjects will be covered minimal panels for 
susceptibility testing for clinical use and for the surveillance of resis- 
tance mechanisms, interpretive standards for streptococci including 
crossresistance for betalactam antibiotics or macrolides in S. pneumo- 
n ia ,  detection of the various resistance mechanisms of enterococci, 
definition of breakpoints for perod or parented cephalosporines, 
fixed or proportional ratio of betalactamase inhibitors, reporting of 
inducible cephalosporinase, methods to detect extended spectrum 
betalactamase producing enterobacteriaceae and methods to detect 
resistance mechanisms to fluoroquinolones. The problem of report- 
ing susceptible organisms according to breakpoint but with a de- 
tectable resistance mechanism will be discussed. The question of 
optimal quality control of susceptibility testing by creating a battery 
of reference strains with defined resistance mechanisms covering a 
broader range of MIC’S will be suggested. 
1 s121 I Development of NCCLS Antimicrobial 
Susceptibility Testing guidelines in the global 
environment 
M.J. Ferraro. Mass General Hospital, Harvard Medical School, Boston, 
MA, USA 
NCCLS is a global association ofmore than 2100 organizations and 
institutions in 46 different countries. NCCLS standards, guidelines, 
products, and services promote the delivery of quality patient test- 
ing and healthcare. The NCCLS Subcommittee on Antimicrobial 
Susceptibility Testing is composed of representatives &om microbi- 
ology laboratories, government, health care providers and educators, 
and pharmaceutical and diagnostic microbiology industries. Using 
the NCCLS consensus process, the subcommittee develops stan- 
dards that promote accurate antimicrobial susceptibility testing and 
appropriate reporting. The Subcommittee’s goals are to: 1. develop 
standard reference methods; 2. provide quality control parameters; 3. 
estabhh interpretive criteria; 4. provide suggestions regardug groups 
of antimicrobial agents for testing that encourage clinidy relevant 
and cost-effective laboratory testing; 5. continually refine standards 
and optimize detection of emerging resistance mechanism through 
the development of new or revised methods, interpretive criteria, 
and quahty control parameters; 6. educate users through commu- 
nication of standard guidelines; and 7. foster malogue with users of 
these methods and those who supply them. 
The ultimate purpose of the Subcommittee’s mission is to provide 
useful dormation to enable laboratories to assist the cliniaan inpa- 
tient care, without making recommendations concerning the cknical 
use of spec& antimicrobial agents. 
The success of the NCCLS consensus process lies, in no small 
measure, in the assurance that all interested parties will have a place 
and be heard at the table. In concert with the NCCLS’S consensus 
process and global growth, I welcome the opportunity to exchange 
views with my European colleagues and look forward to future op- 
portunities for harmonization. 
I S122 I Vieuwpoint of the European Industry on 
susceptibility testing 
A. Bryskier. Clinical Pharmacology Anti-infem’uer HMR, Romainville, 
France 
The development of antibacterial agents is divided into numerous 
parts: One is the microbiology section which is itself split into two 
sections: the first is the antibacterial spectrum and activity includ- 
ing break points and quality control strains, and the second is the 
microbiology within the cljn~cal development (phases I1 and 111). 
One of the main concerns for the development of antibiotics is to 
obtain break-points which are the basehe of the clinical develop- 
ment and the chical introduction of the new antibacterial in clinical 
practice. The problem in Europe is very complex, some agencies 
promote their own break-points: France (CFA), United-Kingdom 
(BSAC), Sweden and Germany (DIN), other countries use NC- 
CLS recommendations as well as recommendations h m  one of the 
above-mentioned countries. 
During the Phase II/III trials, NCCLS recommendations (qual- 
ity control s t r a i n s ,  prelutllnary break-points) are usually used 
world-wide, to obtain reliable clinical and microbiological results. 
After application, break-points are “delivered” by the different 
agencies. The most acute problems are the following Merent 
break-points, diEerent loads of the test disks and the quality control 
sttains very or are not proposed. Furthermore, due to the complexity 
of the regulations, the variations in the load dose could be substantial 
among manufacturers even within different batches. 
There is an acute need w i h n  the pharmaceutical industry in 
Europe for standanbation of the methods used to determine 
break-points for the same quality control strains and the same load 
on the disks. 
The NCCLS subcommittee in the USA is now escablishmg an 
ahance with the Japanese NCCLS and is currently working with 
the Pan America Health Organization and in Brazil. 
An alliance has first to be set up in Europe and secondly with 
other organizations to obtain a consensus which will be help to 
pharmaceutical companies as well as Biodiagnostic companies. 
